{"transactions":[{"id":689500,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T20:19:16.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":110546,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-04-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001470831-26-000813","document":"wk-form4_1786565953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000813/wk-form4_1786565953.xml","form_type":"4"}},{"id":689499,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:19:16.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":27.975,"value":279750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":362152,"source":{"system":"sec-edgar","filing":"0001470831-26-000813","document":"wk-form4_1786565953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000813/wk-form4_1786565953.xml","form_type":"4"}},{"id":689498,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:19:16.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":3.7898,"value":37898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."}],"balance_after":372152,"source":{"system":"sec-edgar","filing":"0001470831-26-000813","document":"wk-form4_1786565953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000813/wk-form4_1786565953.xml","form_type":"4"}},{"id":709925,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-14T20:22:34.000Z","date":"2026-07-10","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":120546,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-04-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001470831-26-000714","document":"wk-form4_1784060551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000714/wk-form4_1784060551.xml","form_type":"4"}},{"id":709924,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-14T20:22:34.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":28,"price":29.68,"value":831.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."}],"balance_after":362152,"source":{"system":"sec-edgar","filing":"0001470831-26-000714","document":"wk-form4_1784060551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000714/wk-form4_1784060551.xml","form_type":"4"}},{"id":709923,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-14T20:22:34.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":9972,"price":28.4163,"value":283367.3436,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.13 to $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":362180,"source":{"system":"sec-edgar","filing":"0001470831-26-000714","document":"wk-form4_1784060551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000714/wk-form4_1784060551.xml","form_type":"4"}},{"id":709922,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-14T20:22:34.000Z","date":"2026-07-10","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":3.7898,"value":37898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."}],"balance_after":372152,"source":{"system":"sec-edgar","filing":"0001470831-26-000714","document":"wk-form4_1784060551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000147083126000714/wk-form4_1784060551.xml","form_type":"4"}},{"id":743429,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:30:11.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":32947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":32947,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":32947},"source":{"system":"sec-edgar","filing":"0001193125-26-265913","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000119312526265913/ownership.xml","form_type":"4"}},{"id":770288,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:07:47.000Z","date":"2026-05-18","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":146107,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-26-036885","document":"wk-form4_1779307664.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026036885/wk-form4_1779307664.xml","form_type":"4"}},{"id":770287,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:07:47.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":2978,"price":20.3481,"value":60596.6418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":362152,"source":{"system":"sec-edgar","filing":"0001628280-26-036885","document":"wk-form4_1779307664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026036885/wk-form4_1779307664.xml","form_type":"4"}},{"id":770286,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:07:47.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":12022,"price":19.9619,"value":239981.9618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.52 to $20.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":365130,"source":{"system":"sec-edgar","filing":"0001628280-26-036885","document":"wk-form4_1779307664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026036885/wk-form4_1779307664.xml","form_type":"4"}},{"id":770285,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:07:47.000Z","date":"2026-05-18","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":3.7898,"value":56847.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":377152,"source":{"system":"sec-edgar","filing":"0001628280-26-036885","document":"wk-form4_1779307664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026036885/wk-form4_1779307664.xml","form_type":"4"}},{"id":804666,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-20","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":161107,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804665,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":false,"shares":7080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":558432,"derivative":{"exercise_price":5.4537,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":7080},"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804664,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":false,"shares":7454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":130546,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-04-05","underlying":"Common Stock","underlying_shares":7454},"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804663,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":false,"shares":8226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":56684,"derivative":{"exercise_price":4.4369,"expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":8226},"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804662,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":23.6097,"value":354145.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.355 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":362152,"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804661,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-20","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":3.7898,"value":56847.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":377152,"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804660,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":true,"shares":7080,"price":5.4537,"value":38612.196,"ownership":{"direct":true},"balance_after":362152,"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804659,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":true,"shares":7454,"price":3.7898,"value":28249.1692,"ownership":{"direct":true},"balance_after":355072,"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":804658,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:27:09.000Z","date":"2026-04-16","kind":"exercise","planned":true,"acquired":true,"shares":8226,"price":4.4369,"value":36497.9394,"ownership":{"direct":true},"balance_after":347618,"source":{"system":"sec-edgar","filing":"0001628280-26-026089","document":"wk-form4_1776727626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026026089/wk-form4_1776727626.xml","form_type":"4"}},{"id":832585,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-20","kind":"exercise","planned":true,"acquired":false,"shares":1596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":176107,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":1596},"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832584,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-19","kind":"exercise","planned":true,"acquired":false,"shares":6905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":177703,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":6905},"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832583,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-18","kind":"exercise","planned":true,"acquired":false,"shares":6499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":184608,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":6499},"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832582,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-20","kind":"sale","planned":true,"acquired":false,"shares":1596,"price":18.9513,"value":30246.2748,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832581,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-20","kind":"exercise","planned":true,"acquired":true,"shares":1596,"price":3.7898,"value":6048.5208,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":340988,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832580,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-19","kind":"sale","planned":true,"acquired":false,"shares":6905,"price":18.7842,"value":129704.901,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832579,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-19","kind":"exercise","planned":true,"acquired":true,"shares":6905,"price":3.7898,"value":26168.569,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":346297,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832578,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-18","kind":"sale","planned":true,"acquired":false,"shares":6499,"price":18.8359,"value":122414.5141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":832577,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-20T21:02:58.000Z","date":"2026-03-18","kind":"exercise","planned":true,"acquired":true,"shares":6499,"price":3.7898,"value":24629.9102,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":345891,"source":{"system":"sec-edgar","filing":"0001628280-26-020236","document":"wk-form4_1774040575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026020236/wk-form4_1774040575.xml","form_type":"4"}},{"id":849105,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:47:17.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":36766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":191107,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":36766},"source":{"system":"sec-edgar","filing":"0001628280-26-016874","document":"wk-form4_1773262035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026016874/wk-form4_1773262035.xml","form_type":"4"}},{"id":849104,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-11T20:47:17.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":36766,"price":19.166,"value":704657.156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-016874","document":"wk-form4_1773262035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026016874/wk-form4_1773262035.xml","form_type":"4"}},{"id":849103,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-11T20:47:17.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":36766,"price":3.7898,"value":139335.7868,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":376158,"source":{"system":"sec-edgar","filing":"0001628280-26-016874","document":"wk-form4_1773262035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026016874/wk-form4_1773262035.xml","form_type":"4"}},{"id":856252,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":false,"shares":3817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":227873,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":3817},"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856251,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":false,"shares":1786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":231690,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":1786},"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856250,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":2631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":233476,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":2631},"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856249,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":3817,"price":18.7508,"value":71571.8036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856248,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":true,"shares":3817,"price":3.7898,"value":14465.6666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":343209,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856247,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":1786,"price":18.7369,"value":33464.1034,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856246,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":true,"shares":1786,"price":3.7898,"value":6768.5828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":341178,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856245,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":2631,"price":18.7338,"value":49288.6278,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":339392,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":856244,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-07T00:27:37.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":true,"shares":2631,"price":3.7898,"value":9970.9638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":342023,"source":{"system":"sec-edgar","filing":"0001628280-26-015778","document":"wk-form4_1772843254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026015778/wk-form4_1772843254.xml","form_type":"4"}},{"id":919722,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:37:04.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":450000,"derivative":{"exercise_price":16.76,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001628280-26-005484","document":"wk-form4_1770241022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000162828026005484/wk-form4_1770241022.xml","form_type":"4"}},{"id":963374,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T23:02:57.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":565512,"derivative":{"exercise_price":5.4537,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0002034671-25-000012","document":"wk-form4_1766098974.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000012/wk-form4_1766098974.xml","form_type":"4"}},{"id":963373,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T23:02:57.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":29500,"price":5.4537,"value":160884.15,"ownership":{"direct":true},"balance_after":339392,"source":{"system":"sec-edgar","filing":"0002034671-25-000012","document":"wk-form4_1766098974.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000012/wk-form4_1766098974.xml","form_type":"4"}},{"id":988931,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-25T23:40:40.000Z","date":"2025-11-24","kind":"exercise","planned":true,"acquired":false,"shares":41163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":236107,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":41163},"source":{"system":"sec-edgar","filing":"0002034671-25-000009","document":"wk-form4_1764114037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000009/wk-form4_1764114037.xml","form_type":"4"}},{"id":988930,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-25T23:40:40.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":41163,"price":18.8623,"value":776428.8549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":309892,"source":{"system":"sec-edgar","filing":"0002034671-25-000009","document":"wk-form4_1764114037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000009/wk-form4_1764114037.xml","form_type":"4"}},{"id":988929,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-25T23:40:40.000Z","date":"2025-11-24","kind":"exercise","planned":true,"acquired":true,"shares":41163,"price":3.7898,"value":155999.5374,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":351055,"source":{"system":"sec-edgar","filing":"0002034671-25-000009","document":"wk-form4_1764114037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000009/wk-form4_1764114037.xml","form_type":"4"}},{"id":1015898,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-20T20:11:00.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":false,"shares":24103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":277270,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":24103},"source":{"system":"sec-edgar","filing":"0002034671-25-000006","document":"wk-form4_1760991057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000006/wk-form4_1760991057.xml","form_type":"4"}},{"id":1015897,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-20T20:11:00.000Z","date":"2025-10-16","kind":"sale","planned":true,"acquired":false,"shares":24103,"price":18.8259,"value":453760.6677,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":309892,"source":{"system":"sec-edgar","filing":"0002034671-25-000006","document":"wk-form4_1760991057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000006/wk-form4_1760991057.xml","form_type":"4"}},{"id":1015896,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-20T20:11:00.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":true,"shares":24103,"price":3.7898,"value":91345.5494,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":333995,"source":{"system":"sec-edgar","filing":"0002034671-25-000006","document":"wk-form4_1760991057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000006/wk-form4_1760991057.xml","form_type":"4"}},{"id":1018701,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-15","kind":"exercise","planned":true,"acquired":false,"shares":13289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":301373,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":13289},"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1018700,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":false,"shares":11445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":314662,"derivative":{"exercise_price":3.7898,"expiration_date":"2033-08-08","underlying":"Common Stock","underlying_shares":11445},"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1018699,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":13289,"price":18.842,"value":250391.338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":309892,"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1018698,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-15","kind":"exercise","planned":true,"acquired":true,"shares":13289,"price":3.7898,"value":50362.6522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":323181,"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1018697,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-13","kind":"sale","planned":true,"acquired":false,"shares":11445,"price":18.9205,"value":216545.1225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":309892,"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1018696,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-15T22:00:17.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":true,"shares":11445,"price":3.7898,"value":43374.261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."}],"balance_after":321337,"source":{"system":"sec-edgar","filing":"0002034671-25-000003","document":"wk-form4_1760565614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000203467125000003/wk-form4_1760565614.xml","form_type":"4"}},{"id":1115303,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":24229,"kind":"person","name":"Mazumdar Claire","position":1,"cik":"0002034671","reported_name":"Mazumdar Claire","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T20:16:25.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":421241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after June 9, 2025, subject to the reporting person's continued service with the Issuer through each vesting date."}],"balance_after":421241,"derivative":{"exercise_price":3.36,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":421241},"source":{"system":"sec-edgar","filing":"0000950170-25-084838","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034671/000095017025084838/ownership.xml","form_type":"4"}}]}